Pegasus & CYBERDYNE Launch $60M Physical AI CVC Fund
TL;DR
Pegasus Tech Ventures, the San Jose firm that turned corporate venture into a managed service, has launched a JPY 10 billion (roughly US$60M) corporate venture capital fund with Japanese cybernics pioneer CYBERDYNE as the sole limited partner. Pegasus is the general partner; CYBERDYNE writes the cheque and sets the thesis. The mandate is robotics, physical AI, healthcare, automation and intelligent systems, all pointed at CYBERDYNE's "Human-Cyber-Physical Space" vision of fusing people, AI-robotics and information systems. It is the newest single-LP vehicle on a platform that already runs more than 40 funds and over $2B in assets, and it is a clean signal of where Japanese industrial capital wants exposure as the AI wave moves from screens into the physical world.
Key Takeaways
Venture-Capital-as-a-Service is quietly eating in-house corporate venture. Rather than CYBERDYNE staffing its own venture team, Pegasus runs the fund as GP on the corporate's behalf. This is the model Pegasus has built its whole firm around, and it keeps winning: two months ago it expanded a separate CVC fund with retailer Japanet to $200M. For corporates burned by the high mortality rate of home-grown venture arms, outsourcing the GP function is an increasingly obvious trade.
"Physical AI" is now a fundable line item, not a conference slide. Putting the term directly in the mandate marks the capital rotation away from pure-software LLM bets toward embodied systems: actuation, sensing, locomotion and human-machine interfaces. CYBERDYNE's two-decade HAL exoskeleton lineage gives this particular fund a credible domain anchor in medical and assistive robotics rather than generic robotics tourism.
This is a strategic vehicle first and a financial one second. With a single corporate LP, IRR matters less than pipeline, partnership and optionality. The fund is effectively a global sourcing and co-development engine for CYBERDYNE's aging-society agenda. Founders should read an offer here as a commercial door into Japan and a regulated healthcare channel, not simply as capital.
Japan's demographics are the real limited partner. The stated drivers — aging populations, workforce shortages and rising healthcare demand — are structural, not cyclical. That is a tailwind likely to outlast the current AI hype cycle, and it explains why a CVC fund is anchoring its thesis in rehabilitation, mobility and labor-augmentation robotics rather than chasing frontier models.
Fund Overview
Fund Name: Pegasus Tech Ventures – CYBERDYNE CVC Fund
Fund Size: JPY 10 billion (approximately US$60M)
Stage: Multi-stage, via the Pegasus VCaaS platform
Check Size: Undisclosed
Geography: Global sourcing centered on Silicon Valley, with Japan as the strategic anchor
Focus: Robotics, physical AI, healthcare, automation and intelligent systems (HCPS Cybernics)
Key LPs: CYBERDYNE, Inc. (sole limited partner)
Why This Fund Matters
Corporate venture capital has a credibility problem that almost nobody in the corporate world likes to say out loud: most in-house programs underperform, churn their teams every few years, and get killed in the first downturn when the parent company protects its core P&L. Pegasus's entire pitch is that this is an operating problem, not a capital problem. By acting as a professional GP across dozens of corporate-backed vehicles, it offers continuity, deal access and venture discipline that a single corporate balance sheet rarely sustains alone. The CYBERDYNE fund is another data point that the managed-CVC model is moving from novelty to default for large industrial players, particularly in Asia.
The timing is the more interesting part. Capital is visibly rotating toward "physical AI" — the application of machine learning to machines that move, manipulate and sense the world. The robotics financing environment around this launch is frothy, with nine-figure and even billion-dollar rounds flowing to humanoid and embodied-AI companies. A $60M fund is small in that context, but its value is not the cheque size; it is the combination of a deep-pocketed strategic with a genuine technology base. CYBERDYNE is not a tourist here. Its HAL wearable robot has cleared real regulatory and clinical hurdles in Japan and abroad, which is exactly the kind of moat that hardware founders struggle to build alone.
There is also a geographic logic. Japan is simultaneously one of the most automation-friendly societies on earth and one of the most demographically constrained, which makes it an unusually motivated buyer of labor-augmenting robotics and assistive healthcare technology. A fund that pairs Silicon Valley deal flow with a Japanese industrial and clinical distribution channel is positioned to do something most cross-border CVC cannot: actually land startups into a hard-to-enter but high-willingness-to-pay market.
Finally, the platform context matters. Pegasus claims a portfolio that, across its funds, includes some of the most valuable private companies in the world. Whether or not a founder ever touches those names, the signal is that this is an experienced manager with a real network, not a first-time corporate experiment. For the physical-AI category specifically, that operating maturity is worth more than another generalist seed fund.
The Team
Pegasus Tech Ventures is led by founder and CEO Dr. Anis Uzzaman, who has built the firm into a global VCaaS platform spanning Silicon Valley, Asia and Europe. By the firm's own account it manages more than 40 funds and over US$2B in assets, has invested in more than 300 startups, and runs the Startup World Cup pitch competition as a global sourcing funnel. Pegasus says its cross-fund portfolio has included SpaceX, OpenAI, Anthropic, Airbnb, Coinbase and X (formerly Twitter); founders should treat those as platform-level positions rather than a promise of co-investment.
On the strategic side, CYBERDYNE was founded in 2004 by Professor Yoshiyuki Sankai of the University of Tsukuba, who remains founder and CEO. The company pioneered the field it calls cybernics — fusing human biology with AI, robotics and information systems — and is best known for HAL (Hybrid Assistive Limb), a wearable cyborg device that reads bioelectric signals from the wearer to assist and regenerate physical function. HAL has been deployed across medical, rehabilitation, labor-support, disaster-response and industrial settings. That clinical and industrial footprint is what distinguishes CYBERDYNE from a financial LP simply chasing the robotics narrative.
What This Means for Founders
If you are building in medical or assistive robotics, embodied AI, eldercare and rehabilitation technology, healthcare automation, sensing, or labor-augmentation systems, this is a fund worth a conversation. The most valuable thing on offer is not the cheque; it is a credible path into Japan and access to CYBERDYNE's clinical, regulatory and industrial relationships. For a hardware startup, a strategic partner who has already navigated medical-device approval and large-scale deployment can compress years of go-to-market risk.
The flip side is to go in clear-eyed about incentives. Single-LP strategic funds optimize for the corporate's roadmap, which can mean pressure toward exclusivity, integration or an acquisition outcome that suits the strategic more than it suits your cap table. Before taking the money, get specific about commercial commitments, IP terms and what "strategic alignment" actually obligates you to. The right deal here is one where CYBERDYNE's distribution is additive and the terms keep your optionality intact.
Fund Momentum Take
We like this fund for what it represents more than for its size. It is a well-run manager pairing with a strategic that has an actual technology base and an actual market problem, in a category — physical AI for an aging society — that has durable demand underneath the hype. That is a healthier setup than the generic "corporate wants AI exposure" funds proliferating right now, most of which have no thesis beyond fear of missing out.
The risks are real and worth naming. Hardware and medical robotics are capital-intensive and slow to exit, which sits awkwardly against a $60M fund that will have limited ability to follow on into the large, dilutive rounds these companies eventually need. Single-LP governance can also distort founder incentives when the strategic's commercial agenda and the startup's best outcome diverge. And "physical AI" is, at this moment, a label attracting a lot of indiscriminate capital; some of it will be incinerated.
Our bet (and we will flag this as opinion): the strongest asset in this vehicle is not Pegasus's network or the $60M, but CYBERDYNE's regulated-healthcare distribution in a market that genuinely needs assistive robotics. If the fund concentrates on founders who can plug into that channel, it will punch well above its weight. If it spreads thin across generic robotics deals to chase the narrative, it will look like every other small CVC fund in two years. The thesis is right; execution and discipline will decide whether the returns follow.
Frequently Asked Questions
How big is the Pegasus–CYBERDYNE fund and who is backing it?
The fund is JPY 10 billion, roughly US$60M. Pegasus Tech Ventures is the general partner and CYBERDYNE, Inc. is the sole limited partner, making it a single-LP corporate venture capital vehicle.
What will the fund invest in?
Startups across robotics, physical AI, healthcare, automation and intelligent systems, with a particular tilt toward CYBERDYNE's HCPS Cybernics vision of fusing humans, AI-robotics and information systems.
What is Venture-Capital-as-a-Service?
It is Pegasus's model of acting as the professional GP for corporate-backed funds, giving corporations startup exposure, deal access and venture discipline without building and staffing an in-house venture arm.
Why is CYBERDYNE doing this?
To accelerate technology development, business co-creation and global expansion around aging populations, workforce shortages and rising healthcare demand — structural problems that map directly onto its assistive-robotics technology such as the HAL device.
Should founders treat this as financial or strategic capital?
Primarily strategic. The biggest value is access to Japan and CYBERDYNE's clinical and industrial channels; founders should negotiate commercial and IP terms carefully so strategic alignment does not constrain future optionality.
Have a fund closing to announce? Submit your fund here.
Need help raising capital? Check out our Fundraising Advisory services.